Bicycle Therapeutics PLC (BCYC) stock
BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3080% below fair value
$3.20+0.02 (+0.63%)
Close on Nov 17, 2026Market cap $224.30MP/E –Yield 0.00%
Bicycle Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Bicycle Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$175.18M. For fiscal 2025 it was -$249.68M. The highest annual figure on record is -$1.42M in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$249.68M | – |
| FY2024 | Dec 31, 2024 | -$164.72M | – |
| FY2023 | Dec 31, 2023 | -$60.63M | – |
| FY2022 | Dec 31, 2022 | -$86.11M | – |
| FY2021 | Dec 31, 2021 | -$14.79M | – |
| FY2020 | Dec 31, 2020 | -$17.79M | – |
| FY2019 | Dec 31, 2019 | -$28.61M | – |
| FY2018 | Dec 31, 2018 | -$26.08M | – |
| FY2017 | Dec 31, 2017 | -$1.42M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$40.30M | – |
| Q2 FY2026 | Jun 30, 2026 | -$49.61M | – |
| Q1 FY2026 | Mar 31, 2026 | -$65.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.35M | – |
| Q3 FY2025 | Sep 30, 2025 | -$71.17M | – |
| Q2 FY2025 | Jun 30, 2025 | -$72.79M | – |
| Q1 FY2025 | Mar 31, 2025 | -$86.37M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.40M | – |
| Q3 FY2024 | Sep 30, 2024 | -$39.83M | – |
| Q2 FY2024 | Jun 30, 2024 | -$44.63M | -230.9% |
| Q1 FY2024 | Mar 31, 2024 | -$70.87M | – |
| Q4 FY2023 | Dec 31, 2023 | -$47.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.03M | – |
| Q2 FY2023 | Jun 30, 2023 | $34.10M | – |
| Q1 FY2023 | Mar 31, 2023 | -$46.41M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.31M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.87M | -127.0% |
| Q2 FY2022 | Jun 30, 2022 | -$23.53M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.40M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.44M | – |
| Q3 FY2021 | Sep 30, 2021 | $21.72M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.37M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.71M | -164.8% |
| Q4 FY2020 | Dec 31, 2020 | -$16.62M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.99M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.35M | – |
| Q1 FY2020 | Mar 31, 2020 | $21.16M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.92M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.89M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.61M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.20M | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.85M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.66M | – |
See a number that looks wrong?